Kaken Pharmaceutical Co., Ltd.
KKPCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $150,556,131 | $137,054,214 | $145,961,402 | $184,066,283 |
| - Cash | $54,093,000 | $50,625,000 | $59,561,000 | $61,025,000 |
| + Debt | $3,850,000 | $3,850,000 | $3,850,000 | $3,850,000 |
| Enterprise Value | $100,313,131 | $90,279,214 | $90,250,402 | $126,891,283 |
| Revenue | $94,035,000 | $72,044,000 | $72,984,000 | $76,034,000 |
| % Growth | 30.5% | -1.3% | -4% | – |
| Gross Profit | $58,532,000 | $38,539,000 | $39,556,000 | $41,576,000 |
| % Margin | 62.2% | 53.5% | 54.2% | 54.7% |
| EBITDA | $22,017,000 | $12,566,000 | $9,402,000 | $16,384,000 |
| % Margin | 23.4% | 17.4% | 12.9% | 21.5% |
| Net Income | $13,945,000 | $8,025,000 | $5,440,000 | $9,549,000 |
| % Margin | 14.8% | 11.1% | 7.5% | 12.6% |
| EPS Diluted | 365.42 | 212.66 | 144.79 | 251.44 |
| % Growth | 71.8% | 46.9% | -42.4% | – |
| Operating Cash Flow | $29,780,000 | $2,577,000 | $9,253,000 | $13,336,000 |
| Capital Expenditures | -$4,392,000 | -$2,167,000 | -$2,206,000 | -$3,257,000 |
| Free Cash Flow | $25,388,000 | $410,000 | $7,047,000 | $10,079,000 |